Search results for "Lymph"

showing 10 items of 4590 documents

Circadian variations in antigen-specific proliferation of human T lymphocytes and correlation to cortisol production.

1995

Cortisol is a well-known immunosuppressant when used therapeutically. The present investigation was set out to study if diurnal variations in endogenous cortisol production are reflected by changes in proliferative responses of human lymphocytes to either a mitogen (phytohemagglutinin-A, PHA) or an antigen (tetanus toxoid, TT) stimulus. The study included eight healthy volunteers. Blood was withdrawn at 0200, 0600, 1000, and 1800h for preparation of lymphocytes and determination of cortisol in plasma. Isolated cells were incubated without (baseline activity) or with inclusion of either 1 micrograms PHA or 10 micrograms TT. Proliferation was measured by labelling with 3H-thymidine for 16 h o…

AdultMalemedicine.medical_specialtyCellular immunityHydrocortisoneEndocrinology Diabetes and MetabolismT-LymphocytesEndogenyBiologyLymphocyte ActivationEndocrinologyImmune systemAntigenInternal medicinemedicineTetanus ToxoidHumansCircadian rhythmLymphocyte CountPhytohemagglutininsBiological PsychiatryHydrocortisoneEndocrine and Autonomic SystemsT lymphocyteCircadian RhythmPsychiatry and Mental healthEndocrinologyFemaleMitogensGlucocorticoidmedicine.drugPsychoneuroendocrinology
researchProduct

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis

2014

Abstract Introduction Splanchnic vein thrombosis (SVT) is a serious complication in patients with paroxysmal nocturnal hemoglobinuria (PNH). Mutant PNH clones can be associated with an increased risk of SVT even in the absence of overt disease, but their prevalence in non-selected SVT patients remains unknown. Materials and Methods Patients with objective diagnosis of SVT and without known PNH were tested for the presence of PNH clone using high-sensitivity flow cytometric analysis. Results A total of 202 SVT patients were eligible, 58.4% were males, mean age was 54.6 years (range 17–94), site of thrombosis was portal in 103 patients, mesenteric in 67, splenic in 37, and supra-hepatic in 10…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentParoxysmalHemoglobinuria ParoxysmalHemoglobinuriaGastroenterologyYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicine80 and overmedicineHumansMyeloproliferative neoplasmAgedAged 80 and overVenous Thrombosisbusiness.industryMedicine (all)Splanchnic vein thrombosisHematologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsThrombosisAdolescent; Adult; Aged; Aged 80 and over; Cross-Sectional Studies; Female; Hematopoietic Stem Cells; Hemoglobinuria Paroxysmal; Humans; Male; Middle Aged; Risk Factors; Venous Thrombosis; Young Adult; Hematology; Medicine (all)SurgeryPortal vein thrombosisVenous thrombosisSettore MED/15 - MALATTIE DEL SANGUECross-Sectional StudiesSplanchnic vein thrombosisParoxysmal nocturnal hemoglobinuriaFemaleHemoglobinuriabusiness
researchProduct

Candidal carriage in the oral cavity of human immunodeficiency virus–infected subjects

2002

Abstract Objectives. We sought to assess asymptomatic oral carriage of Candida species and relative density in human immunodeficiency virus-infected (HIV+) subjects, as well as to determine whether yeast carriage is associated with CD4+cell count, HIV-1 RNA quantity, gender, route of HIV transmission, antiretroviral therapy, or smoking. Study Design. A cross-sectional analysis of oral rinses from HIV+ and healthy subjects was undertaken. Oral candidal carriage and relative species were investigated in 42 HIV+ and 41 healthy individuals, all of whom were seen at the Palermo University Department of Oral Sciences, Italy. Data were managed and analyzed by means of the computer software package…

AdultMalemedicine.medical_specialtyColony Count MicrobialAsymptomaticStatistics NonparametricAcquired immunodeficiency syndrome (AIDS)Candidiasis OralInternal medicineHumansMedicineMycological Typing TechniquesSidaCandida albicansGeneral DentistryMycosisCandidaMouthChi-Square DistributionAIDS-Related Opportunistic Infectionsbiologybusiness.industryMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseCD4 Lymphocyte CountCross-Sectional StudiesCarriageOtorhinolaryngologyOral microbiologyCarrier StateImmunologyHIV-1FemaleSurgeryOral Surgerymedicine.symptombusinessViral loadOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology
researchProduct

Permanent Stoma After Low Anterior Resection for Rectal Cancer

2010

BACKGROUND AND OBJECTIVES: A low anterior resection procedure for removing a rectal tumor aims to preserve the sphincter and avoid a permanent stoma. Permanent stomas are primarily necessary in cases of poor anorectal function and local recurrence. The aim of this study was to clarify whether anastomosis-related complications and local recurrence influenced the rate of permanent stomas in a long-term follow-up. METHODS: Of 1032 consecutive patients with rectal cancer, 397 were treated by low anterior resection (R0 and R1 resections) between 1985 and 2007 at the Department of General and Abdominal Surgery of the University Hospital, Mainz (Germany). All patient data were collected prospectiv…

AdultMalemedicine.medical_specialtyColorectal cancerAdenocarcinomadigestive systemStatistics NonparametricPostoperative ComplicationsStoma (medicine)Risk FactorsmedicineHumansDigestive System Surgical ProceduresAgedRetrospective StudiesAged 80 and overChi-Square DistributionLow Anterior ResectionRectal NeoplasmsAbdominoperineal resectionbusiness.industryGeneral surgeryAnastomosis SurgicalGastroenterologySurgical StomasCancerGeneral MedicineMiddle Agedmedicine.diseasedigestive system diseasesSurgeryLogistic ModelsTreatment Outcomesurgical procedures operativemedicine.anatomical_structureLymphatic MetastasisSphincterFemaleNeoplasm Recurrence LocalComplicationbusinessAbdominal surgeryDiseases of the Colon & Rectum
researchProduct

Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer.

2013

To characterize the stage-specific prognostic relevance of preoperative systemic inflammatory response, defined by C-reactive protein (CRP), in colon cancer (CC) patients.Data from CC patients operated on from 1998 to 2007 at three hospitals from three different Nordic countries were collected retrospectively from national registries, local databases and/or patient records. Patients with emergency surgery, infection or auto-immune disease were excluded. Associations between clinical or histopathological variables and CRP were assessed. Patients were followed from the date of surgery to death or end of follow-up. Disease-specific survival (DSS) was the main endpoint.In total, 525 patients wi…

AdultMalemedicine.medical_specialtyColorectal cancerIncreased C-reactive proteinDiseaseGastroenterologyInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingStage (cooking)Stage specificSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overbusiness.industryElevated crpRetrospective cohort studyHematologyGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurgerySurvival RateC-Reactive ProteinOncologyLymphatic MetastasisColonic NeoplasmsFemaleNeoplasm GradingbusinessFollow-Up StudiesActa oncologica (Stockholm, Sweden)
researchProduct

Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery

2005

Background: Population based colorectal cancer survival among patients diagnosed in 1985–89 was lower in Europe than in the USA (45% v 59% five year relative survival). Aims: To explain this difference in survival using a new analytic approach for patients diagnosed between 1990 and 1991. Subjects: A total of 2492 European and 11 191 US colorectal adenocarcinoma patients registered by 10 European and nine US cancer registries. Methods: We obtained clinical information on disease stage, number of lymph nodes examined, and surgical treatment. We analysed three year relative survival, calculating relative excess risks of death (RERs, referent category US patients) adjusted for age, sex, site, …

AdultMalemedicine.medical_specialtyColorectal cancerpopulation based cancer registriescolorectal cancerAdenocarcinomasurvivalsurgerylymph nodesmedicineHumansRegistriesStage (cooking)Risk factorUSASurvival analysisAgedNeoplasm StagingColorectal CancerRelative survivalcolorectal cancer; population based cancer registries; surgery; lymph nodes; survival; USA; Europebusiness.industryGastroenterologyAbsolute risk reductionCancerMiddle Agedmedicine.diseaseSurvival AnalysisUnited StatesConfidence intervalSurgeryEuropeLymphatic MetastasisFemaleColorectal NeoplasmsbusinessGut
researchProduct

Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, gra…

1996

Differentiation induction therapy is being tested in myelodysplastic syndromes to ameliorate maturation defects and to restore normal hematopoietic function. To this end, 17 patients (eight with refractory anemia, two with refractory anemia and ring sideroblasts, and seven with refractory anemia and excess of blast cells) were treated with a combination of all-trans-retinoic acid (ATRA), granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), and alpha-tocopherol for durations of 8-16 weeks. Absolute neutrophil counts increased in all patients; platelet counts increased in five patients with discontinuation of transfusion needs in two of four transfusion-dependent patients. Sti…

AdultMalemedicine.medical_specialtyCombination therapyTretinoinBone Marrowhemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactorMedicineHumansVitamin EErythropoietinAgedAged 80 and overHematologybusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineMiddle Agedmedicine.diseaseGranulocyte colony-stimulating factorBlood Cell CountHematopoiesisHaematopoiesisEndocrinologymedicine.anatomical_structureErythropoietinMyelodysplastic SyndromesErythropoiesisDrug Therapy CombinationFemaleBone marrowbusinessmedicine.drugAnnals of hematology
researchProduct

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autogra…

2011

Contains fulltext : 95663.pdf (Publisher’s version ) (Closed access) We present results of a phase 3 randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first- or second-line treatment. The primary objective was to demonstrate that autografting improves the 5-year event-free survival (EFS) from 30% to 50%. There were 223 enrolled patients, 72% men and 28% women, 83% after first and 17% after second-line treatment. Binet stages were progressive A 13%, B 67%, C 20%; at randomization, 59% were in complete remission, and 41% in less than complete remission. Patients were randomized between autografting (n = 112) and observation (n = …

AdultMalemedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyHematopoietic stem cell transplantationTransplantation AutologousBiochemistryGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurvival rateAgedbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationTranslational research Immune Regulation [ONCOL 3]Cell BiologyHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineEuropeSurvival RateTransplantationTreatment OutcomeAlemtuzumabFemalebusinessmedicine.drug
researchProduct

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

2007

In patients with relapsing-remitting multiple sclerosis (MS), IVIG was shown to reduce the relapse rate and progression of disability. In patients with chronic progressive MS, a beneficial effect of IVIG was not documented in placebo controlled studies. This trial investigated the influence of IVIG in primary (PPMS) and secondary (SPMS) chronic progressive MS. Two-hundred and thirty-one patients stratified for PPMS ( n = 34) and SPMS ( n = 197) were randomly assigned to IVIG 0.4 g/kg per month or to placebo for 24 months. Primary endpoints were 1) the time to sustained progression of disease identified as worsening of the expanded disability status scale (EDSS) sustained for 3 months, and …

AdultMalemedicine.medical_specialtyDiseasePlaceboPlacebosCentral nervous system diseaseDisability EvaluationDegenerative diseaseQuality of lifeRecurrencehemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProspective StudiesDepression (differential diagnoses)AgedExpanded Disability Status Scalebusiness.industryMultiple sclerosisImmunoglobulins IntravenousMiddle AgedMultiple Sclerosis Chronic Progressivemedicine.diseaseSurgeryTreatment OutcomeNeurologyDisease ProgressionFemaleNeurology (clinical)businessMultiple Sclerosis Journal
researchProduct

Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML …

1990

Alpha- and gamma-interferons have been shown to actively suppress hematopoiesis in patients in the chronic phase of chronic myelogenous leukemia in vitro and in vivo. Since both interferons act through different receptors on their hematopoietic target cells, they are expected to be capable of independently inhibiting abnormal blood cell development in patients with chronic myelogenous leukemia. We have utilized recombinant human interferon alfa-2c to treate 11 patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase, who were resistant to previous interferon gamma therapy. Ten of the patients were evaluable for hematologic, cytogenetic and molecular-genet…

AdultMalemedicine.medical_specialtyDrug ResistanceAlpha interferonBiologyCytogeneticsInterferon-gammaInterferonhemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansInterferon gammaInterferon alfaHematologybreakpoint cluster regionHematologyGeneral MedicineMiddle Agedmedicine.diseaseHematologic ResponseRecombinant ProteinsImmunologyInterferon Type ICancer researchDrug EvaluationFemalemedicine.drugChronic myelogenous leukemiaBlut
researchProduct